Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

Polyphor Ltd.. (7/17/18). "Press Release: Polyphor Announces Listing of New Shares Related to the Convertible Loan Facility Agreement with the Wellcome Trust (Ad-hoc Announcement)".

Organisations Organisation Polyphor Ltd. (SIX: POLN)
  Organisation 2 Wellcome Trust, The
Products Product antibody
  Product 2 investment banking
Index term Index term Polyphor–SEVERAL: investment, 201804–201805 IPO CHF155m (€130m) at SIX Swiss Exchange at CHF38/share
Person Person Scott, Kalina (Polyphor 201706– CFO before Bank am Bellevue + UBS + KPMG)
     


Polyphor today announced that 15'758 new registered shares issued from the authorized capital have been listed today on SIX Swiss Exchange. In April 2018 Polyphor and the Wellcome Trust entered into an amendment agreement to the convertible loan facility agreement made available to Polyphor by the Wellcome Trust. In this amendment agreement the Wellcome Trust exercised its right to convert the outstanding loan amount in full immediately prior to the completion of the listing of Polyphor's shares. These shares have a lock-up period ending one year after the first day of trading.


For further information please contact:

Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com


About Polyphor

Polyphor is a clinical stage, Swiss biopharmaceutical company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead product, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology candidate, balixafortide (POL6326), which has achieved clinical proof of concept in a Phase Ib/proof of concept study in combination with eribulin in patients with advanced breast cancer, and a pipeline of further preclinical antibiotics based on its OMPTA platform. Polyphor is based in Allschwil near Basel and is listed on the Swiss Stock Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

   
Record changed: 2018-07-27

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Polyphor Ltd. (SIX: POLN)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top